Case Digest (UDK No. 16838)
Facts:
Pedrito M. Nepomuceno v. President Rodrigo R. Duterte, Secretary Francisco Duque, Department of Health, Inter-Agency Task Force on Emerging Infectious Diseases and Gen. Carlito Galvez Jr. (Ret.), UDK No. 16838, May 11, 2021, the Supreme Court En Banc, Lopez, J., writing for the Court.Petitioner Pedrito M. Nepomuceno sought a writ of mandamus against respondents including President Rodrigo Duterte, Health Secretary Francisco Duque and the Chief Implementer of the National Task Force Against COVID‑19, Gen. Carlito Galvez Jr. (Ret.), asking the Court to compel respondents to observe FDA rules on acquisition, procurement and use of drugs and vaccines, to issue a cease‑and‑desist order halting the purchase and use of the Sinovac COVID‑19 vaccine, and to require that Sinovac and other COVID‑19 vaccines undergo clinical trials in the Philippines before emergency or regular use.
The petition arose from the national government’s announced plan to procure Sinovac vaccines despite public doubts about their efficacy and an absence of locally conducted clinical trials; the Food and Drug Administration (FDA) had already issued an Emergency Use Authorization (EUA) for Sinovac on February 22, 2021. Petitioner alleged respondents unlawfully neglected ministerial duties concerning vaccine trials and public procurement procedures.
The Court first removed President Duterte as a respondent on the ground of presidential immunity from suit, relying on prior decisions such as De Lima v. President Duterte, Soliven, and David v. Macapagal‑Arroyo. The Court then analyzed the petition under Rule 65, Section 3 (writ of mandamus), concluding petitioner failed to identify any statutory provision imposing a ministerial duty on respondents to conduct local clinical trials or to follow ordinary public bidding procedures in the circumstances alleged.
In resolving the substantive claim the Court relied on pandemic‑specific statutory and executive instruments: Republic Act No. 11494 (Bayanihan to Recover as One Act) (granting the President broad powers to adopt WHO/CDC‑based measures and specifically waiving Phase IV trial requirements for three months in Sec. 12), Executive Order No. 121 (authorizing the FDA Director‑General to issue EUAs and prescribing conditions), and Republic Act No. 11525 (COVID‑19 Vaccination Program Act of 2021) (explicitly exempting vaccine procurement from public bidding and authorizing negotiated procurement). Applying those authorities, and noting that the EUA mechanism allows reliance on foreign regulatory actions and precludes the need for completed local clinical trials, the Court found no legal basis for mandamus and no showing that the EUA was issued unlawfully.
Finally, the Court he...(Subscriber-Only)
Issues:
- Is the incumbent President of the Philippines a proper respondent in a mandamus petition seeking to compel actions related to COVID‑19 vaccine procurement and use?
- Did petitioner establish the elements for a writ of mandamus—specifically, a clear legal right and respondents’ failure to perform a ministerial duty—so as to compel additional local clinical trials or ordinary public bidding for the Sinovac vaccine?
- Was direct resort to the Supreme Court proper, or should petitioner have ...(Subscriber-Only)
Ruling:
- (Subscriber-Only)
Ratio:
- (Subscriber-Only)
Doctrine:
- (Subscriber-Only)